Xencor Inc

XNCR

Healthcare|Biotechnology|USA

$15.86

-0.27 (-1.64%)

Tangible Book

$6.86

Upcoming Data Readouts (6)

Dec 2026

Est. completion

P2Biliary Tract Cancer

XmAb20717 in Advanced Biliary Tract Cancers

Feb 2027

Est. completion

P1Clear Cell Renal Cell Carcinoma

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

Dec 2027

Est. completion

P1Ovarian Cancer

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

Apr 2028

Est. completion

P1P2Ulcerative Colitis (UC)

Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis

Jun 2028

Est. completion

P1Rheumatoid Arthritis

A Phase 1b Open-label Study to Evaluate Safety of Plamotamab in Participants With Rheumatoid Arthritis

Oct 2028

Est. completion

P1Healthy

A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases

Trials past primary completion date but still active — data readout may be imminent.

Oct 2025

A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies